An interventional study of Home monitoring and usual medical monitoring in Congenital Heart Defect, sponsored by Nantes University Hospital. Recruiting at 1 site in France. Open to participants aged 0 Minutes to 36 Months. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Nantes University Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Heart Defects, Congenital with a site in France — 19 open to participants now, 22 under way, none of them phase 3. Heart Defects, Congenital · France.
Among the 73 studies in Heart Defects, Congenital with a site in France, this one is the 12th largest by planned enrollment of the 34 interventional ones that give a count, is one of 10 that started in 2025, is one of 27 with no phase, reaches primary completion later than 18 of the 21 other live ones, and was the 63rd registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →19 of the 73 studies in Heart Defects, Congenital with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 0–18
Nantes University Hospital · Sites in France
Ages up to 6 mo
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages up to 50
University Hospital, Bordeaux · Sites in France
Ages 18+ · Women only · Healthy volunteers
University Hospital, Bordeaux · Sites in France
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: 0 Minutes to 36 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 186 is above the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 91 across the 34 interventional studies, 300 across the 39 observational. Of the 39 that completed or were terminated, 5 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 73 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Nantes University Hospital has 5 studies filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
5 of the studies in Heart Defects, Congenital with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823635Fondation Hôpital Saint-JosephAn International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects | 2026-12-31 |
| NCT04591392atHeart MedicalSafety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD | 2027-03 |
| NCT07864129University Hospital, Strasbourg, FranceVolution of Pulmonary Artery Dimensions in Tetralogy of Fallot | 2027-04-18 |
| NCT06998290University Hospital, BordeauxFeasibility of Home Telemonitoring of Infants With Congenital Heart Disease Awaiting Surgery During the First Year of Life | 2027-06-01 |
| NCT06442592Nantes University HospitalCharacterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects | 2027-07-08 |
Add all 5 to your calendar (.ics) → With an account.
Among the 73 studies in Heart Defects, Congenital with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
We hypothesize that a home monitoring program combined with routine postoperative care significantly reduces morbidity and mortality after neonatal and pediatric cardiac surgery. This project differs from the previously published experiences by (a) providing an innovative telemedicine solution via the use of validated measurement sensors, (b) an alert system based on individualized standards, established for each care pathway, and (c) a protocolized response from medical teams in the management of alerts generated by the home monitoring tool.
Affecting 12-million people worldwide and 7,400 newborns/year in France, congenital heart defects (CHD) are the leading cause of birth defects and a major cause of morbidity and mortality in childhood.
It is (a) a growing patient population, due to an increase in birth prevalence and survival, and (b) a major public health issue, due to a substantial use of healthcare resources and a dramatic impact on quality of life. CHDs concerned by the OSCAR project are rare diseases (prevalence \<1/2000 births) operated on at birth or in infancy. These CHDs expose affected newborns/infants to the risk of major cardiovascular events (fainting, cyanosis, arrhythmias) and/or rapid cardiac decompensation occurring at home in the postoperative period, justifying close ambulatory monitoring to detect early warning signs of complication or decompensation (such as oxygen desaturation, accelerated heart rate, poor weight gain, altered tone, etc.)
This risk is particularly high in certain critical postoperative situations, such as when the physiology of a single ventricle is palliated by a shunt (modified Blalock-Taussig systemic-pulmonary anatomy), or in the intermediate period (interstage) between two palliative surgeries in a Norwood program. In view of the high ambulatory mortality (12-20% in current series) during the interstage of a Norwood program, some expert centers around the world have opted not to discharge operated neonates home, preferring to keep in-hospital monitoring during 4 to 5 months, until stage 2, thus reducing mortality during this critical period. In Anglo-Saxon countries, an outpatient monitoring program has been developed as an alternative for these vulnerable patients, sometimes accompanied by a telemedicine solution, greatly reducing postoperative mortality. This type of outpatient follow-up program does not exist in France.
Inclusion Criteria:
Non Inclusion Criteria:
The usual medical monitoring for the first six months postoperatively is standardized between the 4 university hospital centres concerned and consists of : 1. during the first 4 weeks: a weekly consultation including a record of intercurrent events (malaise, cyanosis, hyperthermia, eating difficulties), a record of weight and vital constants (oxygen saturation, heart rate), an examination of the sternotomy or thoracotomy scar, a clinical cardiovascular examination, a 12-lead electrocardiogram and a transthoracic echocardiogram. 2. during the following 20 weeks: a consultation at 1, 3 and 6 months including the same assessment procedures.
Other: usual medical monitoring
In addition to the usual post-operative monitoring, OSCAR home monitoring will enable key parameters to be transmitted to the medical team at a discontinuous rate (once a day for 4 weeks, then once a week for 20 weeks) via a brief questionnaire (smartphone application) and measurement sensors (weight, oxygen saturation, heart rate) linked to an interface, from the first day the patient returns home until the 6th month post-operatively. The values entered will be automatically compared with individualized standards established for each child at a multidisciplinary meeting, and any deviation from the standard will generate an alert. and the response of the medical teams will be protocolized.
Other: Home monitoring · Other: usual medical monitoring
The key parameters (heart rate, arterial oxygen saturation, weight) will be measured at home using the measurement tools used by the parents, and tele-transmitted at a discontinuous rate, i.e. once a day for 4 weeks, then once a week for 20 weeks. The measurement tools will be given to the family before discharge from the hospital ward. These parameters will be entered into the Exolis platform, in addition to a very brief questionnaire designed to provide information about the child's diet, muscle tone and any medication he or she is taking. taken by the child. An alert will be automatically generated for the pediatric cardiology team if the data transmitted by the measurement sensors deviates from an individualized standard, defined for each child and/or each care pathway at the multidisciplinary consultation meeting before the child returns home. The response will be standardized on the basis of a protocol shared by the 4 investigating centers.
During the first 4 weeks: a weekly consultation including a record of intercurrent events (malaise, cyanosis, hyperthermia, eating difficulties), a record of weight and vital constants (oxygen saturation, heart rate), an examination of the sternotomy or thoracotomy scar, a clinical cardiovascular examination, a 12-lead electrocardiogram and a transthoracic echocardiogram. During the following 20 weeks: a consultation at 1, 3 and 6 months including the same assessment procedures.
Reducing postoperative morbidity and mortality
The main objective is to evaluate the impact of home monitoring in reducing postoperative morbidity and mortality in patients aged 0 to 36 months who have undergone MCC.
Time frame: 6th month post-op
Children's quality of life
Assess the impact of OSCAR surveillance by comparing the 2 groups: Children's quality of life during the postoperative period.
Time frame: 0,1 month, 3 months and 6 months post op
Parents' quality of life
Assess the impact of OSCAR surveillance by comparing the 2 groups: Parents' quality of life during the postoperative period
Time frame: 0,1 month, 3 months and 6 months post op
Parental stress
Assess the impact of OSCAR surveillance by comparing the 2 groups: Parental stress and family impact during the postoperative period
Time frame: 0,1 month, 3 months and 6 months post op
Children's weight growth
Assess the impact of OSCAR surveillance by comparing the 2 groups: Children's weight growth during the postoperative period
Time frame: 1 month, 3 months and 6 months post op
Post-traumatic stress syndromes
Assess the impact of OSCAR surveillance by comparing the 2 groups: The prevalence of post-traumatic stress syndromes in parents at the postoperative month.
Time frame: 6 months post op
Serious non-cardiovascular events
Assess the impact of OSCAR surveillance by comparing the 2 groups: The rate of serious non-cardiovascular events (in order to study a potential delay in the management of these events in the group with OSCAR monitoring group due to increased follow-up).
Time frame: 6 months post op
Factors other than management
To study the impact of factors other than management (OSCAR monitoring versus management) on the parents' quality of life, parental stress and family impact family impact, children's weight gain, and the presence of post-traumatic stress post-traumatic stress disorder in the parents 6 months after the operation.
Time frame: 6 months post op
Therapeutic education program
Evaluate the conditions for implementing OSCAR surveillance by assessing : The relevance of the OSCAR therapeutic education program (ETP) for the parents in the group concerned.
Time frame: 6 months post op
Acceptability of monitoring for the parents
Evaluate the conditions for implementing OSCAR surveillance by assessing : The acceptability of monitoring for the parents in the group concerned.
Time frame: 6 months post op
Acceptability of the monitoring for the medical teams
Evaluate the conditions for implementing OSCAR surveillance by assessing : The acceptability of the monitoring for the medical teams (investigating hospital investigating hospital medical teams and the child's routine care medical teams).
Time frame: 6 months post op
Efficiency
Evaluate the conditions for implementing OSCAR surveillance by assessing : its efficiency.
Time frame: 6 months post op
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Jul 2028, 33 months after the start.
Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 33 months is close to that.
Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.